ORIC Pharmaceuticals (ORIC) News Today $9.63 -0.04 (-0.41%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$9.62 -0.01 (-0.05%) As of 06/13/2025 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ORIC Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Down After Insider SellingJune 14 at 2:12 AM | americanbankingnews.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives $19.17 Average PT from AnalystsJune 14 at 1:29 AM | americanbankingnews.comORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Down on Insider SellingORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Down Following Insider SellingJune 12 at 10:27 AM | marketbeat.comMillennium Management LLC Trims Stock Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)Millennium Management LLC cut its stake in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 90.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 27,634 shares of the company's stock after selling 265,889 sharesJune 12 at 3:08 AM | marketbeat.comBrokers Issue Forecasts for ORIC FY2026 EarningsJune 12 at 1:45 AM | americanbankingnews.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Dominic Piscitelli Sells 2,976 SharesORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) CFO Dominic Piscitelli sold 2,976 shares of the business's stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $10.01, for a total transaction of $29,789.76. Following the completion of the sale, the chief financial officer now directly owns 102,117 shares of the company's stock, valued at approximately $1,022,191.17. The trade was a 2.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.June 11, 2025 | marketbeat.comOric Pharmaceuticals files to sell 19.23M shares of common stock by selling shareholdersJune 11, 2025 | msn.comCantor Fitzgerald Weighs in on ORIC FY2026 EarningsORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) - Cantor Fitzgerald issued their FY2026 EPS estimates for ORIC Pharmaceuticals in a report issued on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal anticipates that the company will post earnings per share of ($2.15) for the year. CanJune 11, 2025 | marketbeat.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Rating of "Buy" from AnalystsORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) has received an average rating of "Buy" from the eight research firms that are currently covering the firm, Marketbeat.com reports. Eight investment analysts have rated the stock with a buy recommendation. The average 12 month price objectJune 11, 2025 | marketbeat.comInsider Selling: ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Sells 2,600 Shares of StockJune 10, 2025 | insidertrades.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Sells $26,026.00 in StockORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) CFO Dominic Piscitelli sold 2,600 shares of the company's stock in a transaction on Friday, June 6th. The stock was sold at an average price of $10.01, for a total transaction of $26,026.00. Following the transaction, the chief financial officer now owns 104,164 shares in the company, valued at approximately $1,042,681.64. The trade was a 2.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.June 9, 2025 | marketbeat.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Acquired by Bank of America Corp DEBank of America Corp DE boosted its stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 34.0% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 112,520 shares of the company's stock after purchasing an additional 28,570 shares during the period. BanJune 8, 2025 | marketbeat.comORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)June 6, 2025 | globenewswire.comORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up - Still a Buy?ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up - Should You Buy?June 6, 2025 | marketbeat.comTwo Sigma Investments LP Decreases Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)Two Sigma Investments LP decreased its holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 24.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 139,683 shares of the company's stock afJune 6, 2025 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Trading 7.6% Higher - Still a Buy?ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 7.6% - Should You Buy?June 4, 2025 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 3.5% - Should You Sell?ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Down 3.5% - Here's WhyJune 3, 2025 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Sees Large Volume Increase - Time to Buy?ORIC Pharmaceuticals (NASDAQ:ORIC) Sees Strong Trading Volume - Here's What HappenedJune 3, 2025 | marketbeat.comResearch Analysts Set Expectations for ORIC FY2025 EarningsORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for ORIC Pharmaceuticals in a research report issued on Thursday, May 29th. Cantor Fitzgerald analyst P. Agrawal forecasts that the company will post earnings of ($1June 2, 2025 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Down - What's Next?ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Down - Should You Sell?May 31, 2025 | marketbeat.comORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for ...May 30, 2025 | morningstar.comTraders Purchase High Volume of ORIC Pharmaceuticals Call Options (NASDAQ:ORIC)ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) was the target of some unusual options trading on Thursday. Investors acquired 8,284 call options on the company. This is an increase of 3,533% compared to the average volume of 228 call options.May 30, 2025 | marketbeat.comWedbush Reiterates "Outperform" Rating for ORIC Pharmaceuticals (NASDAQ:ORIC)Wedbush restated an "outperform" rating and set a $20.00 target price on shares of ORIC Pharmaceuticals in a research note on Thursday.May 30, 2025 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up - Should You Buy?ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up - Here's WhyMay 30, 2025 | marketbeat.comOric Pharma Stock Hits 3-Month High On Promising Results In Prostate Cancer TrialMay 30, 2025 | msn.comORIC Pharmaceuticals shares surge on promising trial dataMay 29, 2025 | in.investing.comORIC Pharmaceuticals Shares Rally 20% on Encouraging Cancer Drug Trial and Funding UpdateMay 29, 2025 | msn.comORIC Pharmaceuticals Touts Positive Efficacy, Safety Data From Early-Stage Prostate Cancer Candidate, Raises CapitalMay 29, 2025 | benzinga.comORIC® Pharmaceuticals Announces $125 Million Private Placement FinancingMay 29, 2025 | tmcnet.comOric Pharma Shares Rise 18% on Cancer Drug Results, Private Placement NewsMay 29, 2025 | marketwatch.comORIC Pharmaceuticals, Inc. (ORIC) Secures $125M to Advance ORIC-944 Phase 3 TrialsMay 29, 2025 | insidermonkey.comORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPCMay 28, 2025 | globenewswire.comORIC® Pharmaceuticals Announces $125 Million Private Placement FinancingMay 28, 2025 | globenewswire.comORIC® Pharmaceuticals to Participate in Upcoming Investor ConferencesMay 27, 2025 | globenewswire.comORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPCMay 27, 2025 | globenewswire.comFrazier Life Sciences Management L.P. Sells 254,617 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)Frazier Life Sciences Management L.P. trimmed its holdings in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 6.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,888,238 shares of the company's stock after selMay 23, 2025 | marketbeat.comCantor Fitzgerald maintains Overweight on ORIC sharesMay 22, 2025 | uk.investing.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Average Rating of "Buy" by BrokeragesShares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) have earned a consensus rating of "Buy" from the eight brokerages that are covering the stock, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a buy rating. The average 12 month price objectMay 19, 2025 | marketbeat.comSphera Funds Management LTD. Acquires 144,817 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)Sphera Funds Management LTD. lifted its stake in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 112.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 273,213 shares of the companyMay 18, 2025 | marketbeat.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Purchased by NEA Management Company LLCNEA Management Company LLC raised its stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 4.4% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 1,566,081 shares of the company's stock after buying an additional 66,081 shares during the qMay 15, 2025 | marketbeat.comDimensional Fund Advisors LP Acquires 103,237 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)Dimensional Fund Advisors LP increased its holdings in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 16.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 717,188 shares of the compMay 13, 2025 | marketbeat.comBalyasny Asset Management L.P. Purchases 424,194 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)Balyasny Asset Management L.P. grew its holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 37.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,555,260 shares of the company's stock after purchasing anMay 11, 2025 | marketbeat.comQ2 EPS Forecast for ORIC Pharmaceuticals Raised by AnalystORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) - Equities researchers at Wedbush upped their Q2 2025 earnings per share (EPS) estimates for shares of ORIC Pharmaceuticals in a research note issued to investors on Monday, May 5th. Wedbush analyst D. Nierengarten now forecasts that the compMay 10, 2025 | marketbeat.comOppenheimer Cuts ORIC Pharmaceuticals (NASDAQ:ORIC) Price Target to $12.00Oppenheimer cut their target price on shares of ORIC Pharmaceuticals from $15.00 to $12.00 and set an "outperform" rating on the stock in a research note on Tuesday.May 8, 2025 | marketbeat.comCantor Fitzgerald Reiterates "Overweight" Rating for ORIC Pharmaceuticals (NASDAQ:ORIC)Cantor Fitzgerald reiterated an "overweight" rating on shares of ORIC Pharmaceuticals in a report on Tuesday.May 8, 2025 | marketbeat.comORIC Pharmaceuticals Outlines Clinical Development Plans and Financial Updates for ORIC-944 and ORIC-114May 7, 2025 | nasdaq.comORIC Pharmaceuticals (NASDAQ:ORIC) Releases Earnings Results, Beats Estimates By $0.10 EPSORIC Pharmaceuticals (NASDAQ:ORIC - Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.10.May 7, 2025 | marketbeat.comORIC Pharmaceuticals' (ORIC) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and set a $21.00 price target on shares of ORIC Pharmaceuticals in a research note on Monday.May 7, 2025 | marketbeat.comORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational UpdatesMay 5, 2025 | globenewswire.comSchonfeld Strategic Advisors LLC Buys New Stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)Schonfeld Strategic Advisors LLC acquired a new stake in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 724,319 shares of the company's stMay 5, 2025 | marketbeat.com Get ORIC Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter. Email Address ORIC Media Mentions By Week ORIC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ORIC News Sentiment▼0.700.89▲Average Medical News Sentiment ORIC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ORIC Articles This Week▼204▲ORIC Articles Average Week Get ORIC Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Immunovant News Today HUTCHMED News Today ImmunityBio News Today Ascentage Pharma Group International News Today Organon & Co. News Today Apellis Pharmaceuticals News Today Xenon Pharmaceuticals News Today Amneal Pharmaceuticals News Today Mirum Pharmaceuticals News Today Arrowhead Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ORIC) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ORIC Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ORIC Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ORIC Stock Free ORIC Stock Alerts